- Home
- FRME vs NVCR Comparison
FRME vs NVCR Comparison
Compare FRME & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- NVCR
- Stock Information
- Founded
- FRME 1893
- NVCR 2000
- Country
- FRME United States
- NVCR Switzerland
- Employees
- FRME N/A
- NVCR N/A
- Industry
- FRME Major Banks
- NVCR Medical/Dental Instruments
- Sector
- FRME Finance
- NVCR Health Care
- Exchange
- FRME Nasdaq
- NVCR Nasdaq
- Market Cap
- FRME 2.1B
- NVCR 1.9B
- IPO Year
- FRME N/A
- NVCR 2015
- Fundamental
- Price
- FRME $40.74
- NVCR $17.71
- Analyst Decision
- FRME Buy
- NVCR Buy
- Analyst Count
- FRME 4
- NVCR 6
- Target Price
- FRME $44.75
- NVCR $32.83
- AVG Volume (30 Days)
- FRME 358.4K
- NVCR 1.6M
- Earning Date
- FRME 07-23-2025
- NVCR 07-24-2025
- Dividend Yield
- FRME 3.53%
- NVCR N/A
- EPS Growth
- FRME 2.61
- NVCR N/A
- EPS
- FRME 3.55
- NVCR N/A
- Revenue
- FRME $615,411,000.00
- NVCR $621,711,000.00
- Revenue This Year
- FRME $15.14
- NVCR $5.56
- Revenue Next Year
- FRME $5.03
- NVCR $9.19
- P/E Ratio
- FRME $11.47
- NVCR N/A
- Revenue Growth
- FRME N/A
- NVCR 18.27
- 52 Week Low
- FRME $32.28
- NVCR $14.17
- 52 Week High
- FRME $46.13
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- FRME 70.16
- NVCR 51.32
- Support Level
- FRME $37.65
- NVCR $17.53
- Resistance Level
- FRME $37.82
- NVCR $18.70
- Average True Range (ATR)
- FRME 1.31
- NVCR 0.72
- MACD
- FRME 0.48
- NVCR 0.09
- Stochastic Oscillator
- FRME 94.15
- NVCR 60.56
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.